Biomerica, Inc. (BMRA)
Nasdaq · Healthcare · Medical Devices
$2.05−4.30%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $9.4M
- Forward P/E
- 5.3
- 52-week range
- $1.45 – $3.21
- 52-week change
- −24.65%
- EPS (trailing)
- −$1.30
Fiscal year to May 2026
- Revenue
- $4.5M (−16.16%)
- Net income
- −$3.8M
- Operating margin
- −119.5%
- Diluted EPS
- −$1.30
From the company’s annual report on SEC EDGAR.
About Biomerica, Inc.
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels. It also provides contract development and manufacturing services to third parties. In addition, the company commercializes inFoods IBS product through physician-directed and laboratory-based channels, such as third-party reimbursement pathways.
Headquarters: Irvine, United States · 50 employees · biomerica.com